Skip to main content
Clinical Trials/NCT03325036
NCT03325036
Completed
Not Applicable

Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication

National Taiwan University Hospital1 site in 1 country60 target enrollmentJuly 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancers Patients
Sponsor
National Taiwan University Hospital
Enrollment
60
Locations
1
Primary Endpoint
Disease progression
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Registry
clinicaltrials.gov
Start Date
July 1, 2017
End Date
December 30, 2024
Last Updated
4 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department.

Exclusion Criteria

  • Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.

Outcomes

Primary Outcomes

Disease progression

Time Frame: Three years

Tumor local recurrence or distant metastasis

Study Sites (1)

Loading locations...

Similar Trials